November 1st 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
18th Annual Controversies in Modern Eye Care
May 4, 2024
Register Now!
Headed to ARVO? You’re invited to dinner COPE CE/CME. Or join virtually!
May 6 & 7, 2024
Register Now!
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
The Ins and Outs of Lubricating Eye Drops
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
AMO sets sights on new horizon
September 15th 2002Santa Ana, CA-"A new coMpany is bOrn" announced the print advertisement that appeared recently in the ophthalmic journals. The rays of a rising sun burst forth over an optic planet, symbolic of the dawning of a new company with "the future of sight."
Read More
Online evaluation helps consumers decide if LASIK is right for them
September 15th 2002Newton Square, PA-Consumers now have an interactive tool to help them determine if LASIK is right for them. The new "Am I a Candidate for LASIK?" feature can be found on www.AllAboutVision.com, an eye health Web site.
Read More
Macugen research: Enrollment ends early in trials for wet AMD drug
September 15th 2002New York-Eyetech Pharmaceuticals Inc. has completed enrollment in two phase III trials of Macugen, its treatment for wet age-related macular degeneration (AMD), and has received $54.2 million from investors for further development of the drug.
Read More
CK an effective approach for hyperopia, presbyopia
August 15th 2002Philadelphia-Conductive keratoplasty (CK), a collagen shrinking procedure, has produced good visual results for patients treated for hyperopia and presbyopia, according to researchers at the annual meeting of the American Society of Cataract and Refractive Surgery.
Read More
Phakic lens holds promise for correcting high myopia, hyperopia
August 1st 2002Philadelphia-Patients with high myopia and high hyperopia seemed to have a good response to the implantation of the Phakic Refractive Lens (PRL, Medennium Inc.), according to Kenneth J. Hoffer, MD, who reported on the phase III trial for myopia and the phase II trial for hyperopia during the American Society of Cataract and Refractive Surgery meeting here.
Read More
Many still focus on controlling IOP, despite new definition
July 15th 2002New York-The official definition of glaucoma has changed over the years to downplay the role of IOP, although IOP does remain a central issue in the treatment and prevention of the condition. Such was the conclusion drawn from discussions at the Glaucoma 2002 meeting here.
Read More
Anti-VEGF therapy holds promise for CNV in AMD
July 1st 2002Fort Lauderdale, FL-Anti-vascular endothelial growth factor (anti-VEGF) therapy is a promising treatment of neovascularization brought on by various ocular diseases, including age-related macular degeneration (AMD), according to Lawrence J. Singerman, MD.
Read More
Softer sell on deck for prescription drugs
July 1st 2002As of July 1, a new marketing code adopted by the Pharmaceutical Research and Manufacturers of America (PhRMA) takes effect. The code would put an end to gifts and dinners for doctors and their staffs, and even cash giveaways, in addition to all forms of recompense that have nothing to do with patient education.
Read More
Ocular allergy signs, symptoms best handled after specifics answered
April 15th 2002Ocular allergies are a major source of discomfort and annoyance. Allergic symptoms often interfere with such common activities as reading, sports, or working on a computer. Greater public awareness of allergic conditions and less tolerance of their signs and symptoms are driving the need for better diagnosis and treatment.
Read More
Greater IOP-lowering effect of drug seen in black population
March 1st 2002Memphis, TN-Travoprost 0.004% ophthalmic solution (Travatan, Alcon) is an effective IOP-lowering medication in patients of all racial origins. However, travoprost reduces IOP more in black patients compared with non-black patients, and its efficacy in blacks exceeds that associated with both timolol (Timoptic, Merck) and latanoprost (Xalatan, Pharmacia), said Peter A. Netland, MD, PhD.
Read More